Teva Pharmaceutical Industries (TEVA) Invested Capital (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Invested Capital for 18 consecutive years, with $24.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital rose 1.2% year-over-year to $24.3 billion; the trailing twelve-month figure through Jun 2026 stood at $24.3 billion (up 1.2% YoY), and the FY2025 full-year result was $24.7 billion, up 6.72% from the prior year.
• Invested Capital eased to $24.3 billion in Q2 2026 per TEVA's latest filing, from $24.9 billion in the prior quarter.
• Across five years, Invested Capital topped out at $33.2 billion in Q1 2022 and bottomed at $22.9 billion in Q1 2025.
• Historically, Invested Capital has averaged $26.9 billion across 5 years, with a median of $26.3 billion in 2024.
• The sharpest annual moves came in 2024 and 2026: Invested Capital declined 17.15% in 2024, then gained 8.46% in 2026.
• Over 5 years, Invested Capital stood at $29.8 billion in 2022, then fell by 6.21% to $28.0 billion in 2023, then slipped by 17.15% to $23.2 billion in 2024, then climbed by 6.72% to $24.7 billion in 2025, then slipped by 1.5% to $24.3 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $24.3 billion, $24.9 billion, and $24.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.